This is an update to my original 2025 AbCellera investment thesis. I am keeping that piece as a record of the original case. This update is about what has changed and what I am watching now.
My ABCL thesis is becoming more specific. The question is no longer only whether AbCellera has an interesting AI-powered antibody-discovery platform. The more important question is whether the company can convert that platform into clinical evidence that changes how investors value the business.
That makes the next set of milestones meaningful. AbCellera expects topline Phase 2 data for ABCL635 in the third quarter of 2026, Phase 1 data for ABCL575 in the fourth quarter, and an IND or CTA submission for ABCL688 in 2027. None of those outcomes is guaranteed. But they give the investment case real events against which it can be tested.
The platform now has to earn clinical credibility
The original attraction of AbCellera was the possibility that its discovery platform, data and integrated capabilities could improve the route from biological target to antibody candidate. That remains the foundation of the story. Platform claims are easier to make than they are to prove, though.
Clinical progress is where the abstraction becomes more concrete. ABCL635 is in a Phase 1/2 study, with the company expecting topline Phase 2 data in the third quarter of 2026. AbCellera has said the Phase 1 portion supported moving into Phase 2 after doses were well tolerated, with no observed liver toxicity or serious adverse events in the interim assessment. That is not proof of commercial success, but it is a more useful signal than a slide deck about platform potential.
ABCL575 is expected to produce Phase 1 topline data in the fourth quarter of 2026. Management has also stated that it currently has no plans to develop that programme beyond Phase 1. I read that as a reminder that not every programme has to become a blockbuster for the platform to create value. It also means I should not give ABCL575 more weight in the thesis than the evidence justifies.
There is more than one shot on goal
What still appeals to me is that AbCellera is not purely a single-asset biotech story. The company has partner programmes and royalty interests alongside its own internal pipeline. ABCL688, an autoimmune candidate from its GPCR and ion-channel platform, is expected to move toward an IND or CTA submission in 2027.
That does not eliminate risk. Partner activity, milestone revenue and royalty economics can be difficult to forecast. The value of multiple shots on goal is not that every one succeeds. It is that the company has several routes through which its discovery and development capabilities could create value over time.
The balance sheet buys time, not certainty
At 31 March 2026, AbCellera reported $504.7 million in cash, cash equivalents and marketable securities. That is a meaningful resource for a company investing in internal programmes and infrastructure. It gives management time to pursue the upcoming clinical milestones without making the next quarter the only thing that matters.
It should not be treated as a free pass. Cash, equivalents and marketable securities were $533.8 million at the end of 2025, and AbCellera remained loss-making in the first quarter. Revenue increased to $8.3 million from $4.2 million in the prior-year quarter, but I view that cautiously because the company’s revenue can be milestone-driven and uneven.
What would strengthen my conviction
- ABCL635 produces credible Phase 2 data and the data supports a clear development path.
- ABCL575 delivers a clean Phase 1 readout, even if the strategic value is primarily platform validation.
- ABCL688 progresses toward its planned 2027 filing.
- The company demonstrates that partner activity and internal programmes can coexist without the platform becoming an expensive science project.
Where I could be wrong
- Early clinical signals may not translate into meaningful efficacy or commercial value.
- Clinical timelines can slip, data can disappoint and development costs can rise.
- AbCellera has no marketed proprietary drugs, so the internal-pipeline case remains unproven.
- Partner fees and milestones can make revenue volatile and difficult to model.
My view now
I still see ABCL as a high-risk, high-uncertainty holding. The reason I remain interested is not a claim that the platform has already won. It is that the next twelve to eighteen months should produce clearer evidence about whether AbCellera can turn an interesting discovery engine into a clinically validated and commercially relevant business.
That is the test. If the clinical milestones strengthen the case, the platform narrative becomes more credible. If they do not, I need to be willing to reassess the thesis rather than defend the original idea.
Sources: AbCellera Q1 2026 Form 10-Q; my original 2025 ABCL investment thesis.
This is my personal investing commentary, not financial advice. I may own shares in AbCellera and can change my view as new information emerges.